Market research
GNMK GenMark Diagnostics, Inc
NASDAQ USD Healthcare
Latest close
—
—
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 2B
- P/E ratio
- Not available
- Analyst target
- 22.52
- Dividend yield
- 0.0%
- Beta
- 3.07
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Medical Devices
- ISIN
- US3723091043
- Market cap
- 2B
- P/E ratio
- Not available
- Analyst target
- 22.52
- Dividend yield
- 0.0%
- Beta
- 3.07
About
About GenMark Diagnostics, Inc
As of April 21, 2021, GenMark Diagnostics, Inc. operates as a subsidiary of Roche Holding AG.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the GNMK discussion.
5 years, 4 months ago
GenMark Diagnostics, Inc is currently in a long term uptrend where the price is trading 41.8% above its 200 day moving average.
From a valuation standpoint, the stock is 99.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 9.4.
GenMark Diagnostics, Inc's total revenue rose by 84.1% to $50M since the same quarter in the previous year.
Its net income has increased by 63.8% to $-4M since the same quarter in the previous year.
Finally, its free cash flow fell by 1.8% to $-10M since the same quarter in the previous year.
Based on the above factors, GenMark Diagnostics, Inc gets an overall score of 4/5.